A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients With Moderate to Severe Atopic Dermatitis. J of Skin 2018, 2 (S1), S29. https://doi.org/10.25251/skin.2.supp.28.